Stock listing

NASDAQ:COGT Cogent Biosciences, Inc. Stock

Home listing (NASDAQ) of Cogent Biosciences, Inc.

Follow Cogent Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:COGT

$26.72 USD -1.09 (-3.9%)

Close on Nov 20, 2026

Past year -23.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$26.62 – $27.83 USDNov 20, 2026
Volume
2.12M sharesNov 20, 2026
Market cap
$4.65B USDAt the close on Nov 20, 2026 · price × 174.0M shares outstanding
52-week range
$26.36 – $43.73 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$65.56M USDMedian day 1.92M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Cogent Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:COGT · Home$26.72 USD-1.095 (-3.9%)2,119,147$27.26$27.83$26.62$27.81Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:COGT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$26.72-1.095-3.9%$27.26$27.83$26.622,119,147
$27.81-0.04-0.1%$27.81$28.77$27.732,711,457
$27.85+0.41+1.5%$27.22$28.08$26.363,363,427
$27.44-1.12-3.9%$28.71$28.81$27.231,449,161
$28.56-0.58-2.0%$29.01$29.02$28.451,150,715
$29.14-0.26-0.9%$29.01$29.78$28.611,858,718
$29.40-2.24-7.1%$31.93$32.33$28.804,513,711
$31.64-1.90-5.7%$33.21$33.65$31.602,850,312
$33.54+1.895+6.0%$32.38$34.04$31.491,689,876
$31.65+2.065+7.0%$29.53$31.69$28.971,481,731
$29.58-1.91-6.1%$31.34$31.41$29.162,724,932
$31.49+0.43+1.4%$32.03$32.03$29.942,229,450
$31.06+1.33+4.5%$30.08$31.27$30.061,876,714
$29.73-1.29-4.2%$31.31$31.48$29.691,998,106
$31.02-0.94-2.9%$31.75$32.34$30.652,495,131
$31.96-0.27-0.8%$32.86$32.86$31.681,507,387
$32.23+0.22+0.7%$31.77$32.68$31.681,740,882
$32.01+1.10+3.6%$31.10$32.22$30.721,838,062
$30.91-0.30-1.0%$31.41$31.55$30.522,205,980
$31.21-0.10-0.3%$30.94$31.27$30.331,771,236
$31.31-0.12-0.4%$31.07$31.91$30.861,178,296
$31.43+0.19+0.6%$31.26$31.94$31.202,099,781
$31.24+1.23+4.1%$30.24$31.50$30.032,311,787
$30.01+0.49+1.7%$29.66$30.23$29.512,541,218
$29.52+0.010.0%$29.47$29.98$28.772,783,048
$29.51+1.36+4.8%$28.33$29.78$28.333,039,765
$28.15+0.06+0.2%$27.93$29.05$27.742,295,507
$28.09-1.69-5.7%$29.46$29.46$27.852,995,450
$29.78-1.22-3.9%$30.81$31.07$29.631,855,295
$31.00+0.92+3.1%$29.98$31.03$29.902,522,272
$30.08-0.06-0.2%$29.71$30.66$28.693,643,985
$30.14-0.24-0.8%$30.05$30.43$29.881,262,894
$30.38-0.49-1.6%$31.17$31.17$29.702,383,802
$30.87-0.15-0.5%$31.26$31.37$29.931,792,883
$31.02-0.57-1.8%$32.12$32.29$30.861,172,134
$31.59-0.43-1.3%$32.02$32.57$31.521,698,630
$32.02+0.36+1.1%$31.74$32.76$31.491,960,172
$31.66-0.20-0.6%$31.76$32.12$31.321,704,731
$31.86-0.45-1.4%$32.00$32.20$31.232,212,923
$32.31+0.88+2.8%$31.55$32.71$31.052,979,048
$31.43+0.02+0.1%$31.21$31.95$30.352,591,471
$31.41-1.22-3.7%$32.62$32.85$30.882,330,314
$32.63+0.63+2.0%$32.23$32.85$32.062,036,175
$32.00+0.50+1.6%$31.97$32.52$31.413,415,438
$31.50-1.69-5.1%$33.21$33.42$31.394,604,077
$33.19+0.65+2.0%$33.07$33.64$32.881,189,539
$32.54-0.20-0.6%$32.89$33.27$32.201,921,689
$32.74-0.67-2.0%$33.37$33.93$32.691,712,424
$33.410.000.0%$33.42$33.58$32.851,437,396
$33.41-0.67-2.0%$34.51$35.00$33.211,715,802
$34.08-0.10-0.3%$33.50$34.19$33.072,264,643
$34.18-1.10-3.1%$35.09$35.57$34.081,587,526
$35.28+0.52+1.5%$34.16$35.75$33.902,244,424
$34.76-0.19-0.5%$34.56$35.20$34.42784,080
$34.95+0.38+1.1%$34.90$35.14$34.061,268,646
$34.57-0.11-0.3%$35.18$35.82$34.011,181,784
$34.68-0.32-0.9%$34.48$34.99$34.301,480,641
$35.00+0.33+1.0%$34.61$35.21$34.111,849,678
$34.67-2.42-6.5%$36.66$36.85$34.531,771,221
$37.09+0.37+1.0%$36.51$37.67$36.411,636,565
$36.72-0.08-0.2%$36.49$37.12$36.281,062,781
$36.80+0.57+1.6%$36.56$37.08$36.441,394,407
$36.23-0.50-1.4%$36.75$37.12$36.071,214,545
$36.73+1.42+4.0%$35.75$37.22$35.402,515,752
$35.31-1.54-4.2%$36.31$36.70$34.911,943,841

Splits

1 split · NASDAQ:COGT · every price before a split is adjusted for it

DayRatioWhat
1-for-4Consolidation
Ticker
NASDAQ:COGT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Cogent Biosciences, Inc. news

Cogent Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
26 in the last 12 months · 150 in all · newest Nov 5, 2026 · oldest 2019
Decks
17 decks · latest September 2026

Where Cogent Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:COGT · Home listing · This pageNASDAQUnited StatesUSD
BX Swiss:COGTBX SwissSwitzerlandCHF
BOATS:COGTBOATSUnited StatesUSD

Valuation

Price/book 9.0× against a median of 6.4×: 7th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$4.08B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
9.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.4×
Beta vs S&P 500
1.30

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Cogent Biosciences, Inc. · NASDAQ:COGTUS$4.65BUS$4.08Bn/an/an/a9.0×n/a0.4×1.30
SK Biopharmaceuticals Co., Ltd. · KRX:326030US$5.08BUS$4.80B16.9×7.5×20.1×6.7×46.6%0.0×n/a
Veradermics, Incorporated · NYSE:MANEUS$5.04BUS$4.25Bn/an/an/a6.3×n/a0.0×1.13
Liquidia Corporation · NASDAQ:LQDAUS$4.90BUS$4.68Bn/a7.5×n/an/a−15.2%n/a0.84
Erasca, Inc. · NASDAQ:ERASUS$4.78BUS$4.18Bn/an/an/a5.2×n/a0.1×1.51
Dianthus Therapeutics, Inc. · NASDAQ:DNTHUS$4.76BUS$3.92Bn/a1,444×n/a3.8×n/a0.0×0.90
PTC Therapeutics, Inc. · NASDAQ:PTCTUS$4.71BUS$3.12Bn/a2.7×n/an/a−9.2%n/a0.88
Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSAUS$4.53BUS$3.97B41.4×4.2×29.9×6.4×11.6%0.0×0.57
Travere Therapeutics, Inc. · NASDAQ:TVTXUS$4.51BUS$4.21Bn/a6.5×n/a200×−18.7%0.0×1.31
Ionis Pharmaceuticals, Inc. · NASDAQ:IONSUS$4.43BUS$4.70Bn/a4.9×n/a11.3×−56.9%5.5×0.40
Edgewise Therapeutics, Inc. · NASDAQ:EWTXUS$4.37BUS$2.63B4.3×n/an/a2.7×n/a0.0×1.12
Median of the othersUS$4.74BUS$4.19B16.9×6.5×25.0×6.4×−12.2%0.0×0.90

Forecasts

9 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
55.82 USD · Analysts' mean
EPS, year to Dec 2026
-2.33 · 9 analysts
Revenue, year to Dec 2026
5.45M · 11 analysts

Team and board

Officers

OfficerRole
Andrew RobbinsChief Executive Officer & President
John GreenChief Financial Officer
Evan KearnsChief Legal Officer and Corporate Secretary
Christi WaarichSenior Director, Investor Relations
Brad BarnettChief Technology Officer
Cole PinnowChief Commercial Officer
Erin SchellhammerChief People Officer
Jessica SachsChief Medical Officer
John RobinsonChief Scientific Officer
Karen FerranteMedical Oncologist and former Pharma-Biotech Executive
Matthew E. RosPharma-Biotech Executive
Todd E. ShegogPharma-Biotech Executive

Board

DirectorRole
Andrew RobbinsChief Executive Officer & President
Arlene M. MorrisDirector
Chris CainMember of the Compensation Committee, Chair of the Science & Technology Committee
Karen FerranteMedical Oncologist and former Pharma-Biotech Executive
Matthew E. RosPharma-Biotech Executive
Peter HarwinFounding Partner, Fairmount Funds Management LLC
Todd E. ShegogPharma-Biotech Executive

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+7.0%
Q2 2026Aug 10, 2026 · After close−6.8%
Q1 2026May 12, 2026+0.6%
Q4 2025Feb 17, 2026 · Before open+3.0%
Q3 2025Nov 7, 2025 · After close+119.0%
Q2 2025Aug 5, 2025 · Before open−5.7%
Q1 2025May 5, 2025 · Before open−5.1%
Q4 2024Feb 25, 2025 · Before open−6.3%
Q3 2024Nov 12, 2024 · Before open−0.2%
Q2 2024Aug 6, 2024 · Before open+1.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · Before open+2.5%
Q4 2023Feb 26, 2024 · Before open+0.8%
Q3 2023Nov 2, 2023 · Before open+4.5%
Q2 2023Aug 8, 2023 · Before open+7.6%
Q1 2023May 9, 2023 · Before open+2.5%
Q4 2022Mar 14, 2023 · Before open+7.5%
Q3 2022Nov 14, 2022 · Before open−2.3%
Q2 2022Aug 9, 2022 · Before open+3.1%
Q1 2022May 10, 2022 · Before open−8.3%
Q4 2021Mar 15, 2022 · Before open+4.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck56 slidesSeptember 2026
Technical Presentation (2026)Technical16 slides2026
Investor Presentation (December 2025)Investor deck33 slidesDec 8, 2025
ASH 2025Conference16 slidesDecember 2025
Technical Presentation (November 2025)Technical21 slidesNov 10, 2025
Technical Presentation (July 2025)Technical18 slidesJul 7, 2025
Jefferies Global Healthcare Conference 2025Conference15 slidesJun 5, 2025
ASH 2023 Annual Meeting (Oral Presentation)Conference17 slidesDecember 2023
CTOS Annual Meeting 2023Conference11 slidesNov 1, 2023
American Society of Hematology Annual Meeting 2022Conference22 slidesDec 12, 2022
All 17 decks
DeckKindSlidesDate
European Hematology Association Congress 2022Conference24 slidesJun 10, 2022
Investor Presentation (November 2020)Investor deck31 slidesNov 30, 2020
Unum Therapeutics — Investor Presentation (October 2020)Investor deck22 slidesOct 5, 2020
Unum Therapeutics — Merger or Acquisition (July 2020)Merger or acquisition22 slidesJul 6, 2020
Unum Therapeutics — Investor Presentation (January 2020)Investor deck28 slidesJan 13, 2020
Unum Therapeutics — Cowen and Company 39th Annual Healthcare Conference 2019Conference28 slidesMar 7, 2019
Unum Therapeutics — Investor Presentation (January 2019)Investor deck39 slidesJan 7, 2019

Open Decks

Financings

RaiseDate
At-the-market programme of shares
Closed: US$73.6M raised
Use of proceeds: Fund operating expenses and capital expenditures into late 2028, including through potential FDA approvals of bezuclastinib and early commercial launch
Aug 10, 2026
1.625% convertible senior notes due 2031
Update: US$200M · Jefferies +1
Dealers: Jefferies (co-lead), J.P. Morgan (co-lead)
Use of proceeds: Repay $50 million of term loans; bezuclastinib development, regulatory work and commercial launch; other candidates; working capital and general purposes
Nov 11, 2025
Public offering of shares of common stock
Made bigger: US$200M · US$31 a share · J.P. Morgan +5
Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Leerink Partners (co-lead), Guggenheim Securities (co-lead), LifeSci Capital, Raymond James
Use of proceeds: Repay $50 million of term loans; bezuclastinib development, regulatory work and commercial launch; other candidates; working capital and general purposes
Nov 11, 2025
At-the-market programme of shares of common stock
Closed: US$39M raised
Nov 3, 2025
Public offering of shares of common stock
Closed: US$230M raised · US$9 a share · J.P. Morgan +3
Dealers: J.P. Morgan (co-lead), Leerink Partners (co-lead), Guggenheim Securities (co-lead), LifeSci Capital
Use of proceeds: Development, regulatory and commercial preparation for bezuclastinib and other candidates, its commercial launch, working capital and general corporate purposes
Jul 10, 2025
At-the-market programme of common stock
Closed: US$25M raised
Feb 25, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Unum Therapeutics, Inc. Priced at US$12.00 a share on Mar 28, 2018.

Price
US$12.00 a share
Shares offered
5,770,000 shares of common stock
Offering size
US$69.2 million
Underwriters' option
Up to 865,500 more shares
Underwriters
MORGAN STANLEY, COWEN, SUNTRUST ROBINSON HUMPHREY, WEDBUSH PACGROW · In the order on the cover
Shares delivered
On or about Apr 3, 2018

Steps

StepWhen
Draft sent to the SEC in confidenceNov 3, 2017
Filed publiclyMar 2, 2018
Amended onceMar 19, 2018
Shares registered with an exchangeMar 26, 2018
Declared effective by the SECMar 28, 2018
Final prospectus, with the priceMar 29, 2018

Open IPO · From the cover of the final prospectus (424B4) filed Mar 29, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue000007.87M22.5M9.73M8.36M6.36M
Cost of revenue4.62M4.40M3.59M5.88M147.0K25.7M43.7K
Gross profit-4.62M-4.40M-3.59M-5.88M-147.0K-17.9M22.5M9.73M8.36M6.36M
Research and development269.8M232.7M173.8M121.6M55.9M25.7M43.7M38.3M29.8M22.0M
Selling, general and administrative63.6M43.3M34.4M26.2M19.6M17.4M11.0M7.45M4.68M3.43M
Operating income-333.4M-275.9M-208.1M-147.8M-75.6M-82.2M-32.2M-36.0M-26.2M-19.1M
Depreciation and amortization2.60M2.50M2.30M800.0K147.0K720.0K1.29M1.32M1.17M830.0K
EBITDA-330.8M-273.4M-205.8M-147.0M-75.4M-81.5M-30.9M-34.7M-25.0M-18.2M
Interest expense3.06M003.99M3.13M144.0K0000
Income before tax-328.9M-255.9M-192.4M-140.2M-72.3M-74.8M-31.8M-34.5M-25.5M-18.1M
Income tax0-7.60M-467.0K-8.36M-1.56M1.47M-386.0K-265.0K
Net income-328.9M-255.9M-192.4M-140.2M-72.3M-74.8M-31.8M-34.5M-25.5M-18.1M
Earnings per share, basic-2.16-1.94-1.94-1.73-1.87-16.17-4.18-1.39-2.51-2.45
Earnings per share, diluted-2.16-1.94-1.94-1.73-1.87-16.17-4.18-1.39-2.51

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents312.0M98.2M53.2M139.9M219.7M242.2M37.4M55.7M28.3M41.3M
Short-term investments588.8M188.9M212.5M119.4M0022.9M12.7M27.2M
Receivables02.00M1.67M830.0K928.0K
Inventory75.0K
Current assets910.4M296.5M270.8M265.0M222.6M244.9M40.6M81.0M42.4M69.7M
Property, plant and equipment5.46M6.47M8.34M7.78M1.71M134.0K1.86M3.25M4.11M
Total assets937.6M327.9M313.4M300.8M232.1M250.9M49.4M85.9M49.1M75.5M
Accounts payable9.50M12.0M10.7M5.84M3.48M732.0K3.18M1.52M1.35M1.45M
Current liabilities64.0M55.7M38.2M26.8M17.1M13.1M13.2M24.9M11.2M8.74M
Long-term debt222.9M0
Total debt222.9M018.9M19.6M3.15M5.21M6.03M
Total liabilities301.2M71.6M55.6M45.1M17.9M16.2M17.7M25.7M20.8M23.2M
Shareholders' equity636.4M256.3M257.8M255.7M214.2M234.7M31.8M60.2M-48.8M52.4M
Shares outstanding161.0M110.5M86.1M69.9M43.8M32.3M7.67M30.1M10.2M7.40M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-264.4M-207.8M-153.6M-118.6M-58.8M-35.9M-41.5M-32.5M-25.8M-18.6M
Capital spending-1.55M-573.0K-2.80M-6.86M-1.72M-320.0K-33.0K-549.0K-912.0K-3.31M
Free cash flow-266.0M-208.4M-156.4M-125.5M-60.5M-35.9M-41.5M-33.0M-26.7M-21.9M
Cash from investing-399.5M38.3M-97.8M-124.7M-1.72M8.42M23.2M-10.5M13.6M-30.4M
Cash from financing878.2M214.5M163.5M163.6M38.0M232.2M108.0K70.3M-729.0K-40.0K
Share buybacks1.61M55.0K124.5M
Change in cash214.3M44.9M-87.9M-79.8M-22.5M204.8M-18.2M27.3M-13.0M-49.1M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
8-K · Current reportSep 2, 2026Material contractSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
144 · Notice of proposed saleAug 27, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
8-K · Current reportAug 10, 2026Current reportSEC
424B5 · ProspectusAug 10, 2026Offer documentSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 10, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 31, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Meeting outcomeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 31, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansFeb 17, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
10-K · Annual reportFeb 17, 2026Annual reportSEC
8-K · Current reportFeb 17, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
144 · Notice of proposed saleJan 22, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 22, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
8-K · Current reportDec 8, 2025Current reportSEC
8-K · Current reportNov 18, 2025Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 17, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 13, 2025Material contractSEC
424B5 · ProspectusNov 12, 2025Offer documentSEC
424B5 · ProspectusNov 12, 2025Offer documentSEC
FWP · Free writing prospectusNov 12, 2025Offer documentSEC
424B5 · ProspectusNov 10, 2025Offer documentSEC
424B5 · ProspectusNov 10, 2025Offer documentSEC
8-K · Current reportNov 10, 2025Current reportSEC
S-3ASR · Registration statementNov 7, 2025Offer documentSEC
10-Q · Quarterly reportNov 7, 2025Quarterly reportSEC
8-K · Current reportNov 3, 2025ResultsSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
8-K · Current reportSep 11, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 14, 2025Big-stake noticeSEC
4 · Change in ownershipJul 14, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 11, 2025Big-stake noticeSEC
8-K · Current reportJul 10, 2025ResultsSEC
424B5 · ProspectusJul 9, 2025Offer documentSEC
424B5 · ProspectusJul 8, 2025Offer documentSEC
8-K · Current reportJul 7, 2025Current reportSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
8-K · Current reportJun 11, 2025Material contractSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
8-K · Current reportJun 5, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMay 12, 2025Other filingsSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
424B5 · ProspectusMay 6, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMay 6, 2025Offer documentSEC
ARS · Annual report to shareholdersApr 22, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 11, 2025Big-stake noticeSEC
PRE 14A · Preliminary proxy statementApr 11, 2025Meeting noticeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 25, 2025Offer documentSEC
10-K · Annual reportFeb 25, 2025Annual reportSEC
8-K · Current reportFeb 25, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
8-K · Current reportDec 9, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 7, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 7, 2024Big-stake noticeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
8-K · Current reportSep 3, 2024Current reportSEC
S-8 · Registration statement for employee plansAug 6, 2024Offer documentSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
8-K · Current reportJun 27, 2024Current reportSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJun 13, 2024Big-stake noticeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
8-K · Current reportJun 5, 2024Meeting outcomeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 29, 2024Insider tradeSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
ARS · Annual report to shareholdersApr 23, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 12, 2024Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 11, 2024Other filingsSEC
CORRESP · Letter to the SECApr 8, 2024Other filingsSEC
UPLOAD · Letter from the SECApr 5, 2024Other filingsSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedApr 1, 2024Big-stake noticeSEC
4 · Change in ownershipApr 1, 2024Insider tradeSEC
S-3 · Registration statementMar 29, 2024Offer documentSEC
SC 13D/A · Big-stake notice, amendedMar 27, 2024Big-stake noticeSEC
8-K · Current reportMar 22, 2024FinancingSEC
S-8 · Registration statement for employee plansFeb 26, 2024Offer documentSEC
10-K · Annual reportFeb 26, 2024Annual reportSEC
8-K · Current reportFeb 26, 2024ResultsSEC
SC 13D/A · Big-stake notice, amendedFeb 16, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 16, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
8-K · Current reportFeb 14, 2024Material contractSEC
SC 13G · Big-stake noticeFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 9, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 5, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 26, 2024Big-stake noticeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 23, 2024Big-stake noticeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
8-K · Current reportDec 11, 2023Current reportSEC
10-Q · Quarterly reportNov 7, 2023Quarterly reportSEC
8-K · Current reportNov 2, 2023ResultsSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
S-8 · Registration statement for employee plansAug 8, 2023Offer documentSEC

This page holds 200 of 616 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Cogent Biosciences, Inc.’s releases · as of Nov 3, 2026

Common shares
173,994,452
Fully diluted
173,994,452

Fully diluted

LineSharesAs of
Common shares173,994,452Nov 3, 2026

Share count over time

CountShares
Nov 3, 2026173,994,452

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Fidelity26.9MUS$860MSep 30, 2026
BlackRock17.2MUS$552MSep 30, 2026
Vanguard17.1MUS$547MSep 30, 2026
State Street7.77MUS$249MSep 30, 2026
Janus Henderson7.43MUS$238MSep 30, 2026
Deerfield Management Company, L.P.5.96MUS$191MSep 30, 2026
Fairmount Funds Management LLC5.5MUS$176MSep 30, 2026
T. Rowe Price5.24MUS$168MSep 30, 2026
Wellington4.68MUS$150MSep 30, 2026
Geode Capital4.48MUS$143MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Kynam Capital Management, LP3.79MUS$121MSep 30, 2026
Polar Capital Holdings Plc3.47MUS$111MSep 30, 2026
Invesco3.22MUS$103MSep 30, 2026
Pictet Asset Management Holding SA2.84MUS$91MSep 30, 2026
TCG Crossover Management, LLC2.5MUS$80.1MSep 30, 2026
Deep Track Capital, LP2.5MUS$80MSep 30, 2026
AllianceBernstein2.44MUS$78MSep 30, 2026
Goldman Sachs2.38MUS$76.1MSep 30, 2026
Octagon Capital Advisors LP2.35MUS$75.2MSep 30, 2026
Rtw Investments, LP2.31MUS$73.9MSep 30, 2026
Driehaus Capital Management LLC2.05MUS$65.7MSep 30, 2026
Orbimed Advisors LLC2MUS$64.2MSep 30, 2026
Woodline Partners LP2MUS$64.1MSep 30, 2026
Candriam S.C.A.1.96MUS$63MSep 30, 2026
Franklin Templeton1.94MUS$61MSep 30, 2026
UBS1.91MUS$61.2MSep 30, 2026
Venrock Adviser, LLC1.64MUS$52.6MSep 30, 2026
Emerald Advisers, LLC1.61MUS$51.7MSep 30, 2026
Siren, L.L.C.1.61MUS$51.5MSep 30, 2026
Schwab1.6MUS$51.4MSep 30, 2026
Silverarc Capital Management, LLC1.57MUS$50.4MSep 30, 2026
Northern Trust1.56MUS$49.8MSep 30, 2026
American Century1.44MUS$46.1MSep 30, 2026
Bank of America1.27MUS$40.5MSep 30, 2026
Commodore Capital LP1.26MUS$40.5MSep 30, 2026
Logos Global Management LP1.25MUS$40MSep 30, 2026
Lord, Abbett & Co. LLC1.19MUS$38MSep 30, 2026
Assenagon Asset Management S.A.1.18MUS$37.9MSep 30, 2026
Loomis Sayles & Co L P1.12MUS$35.7MSep 30, 2026
Emerald Mutual Fund Advisers Trust1.09MUS$34.8MSep 30, 2026
Voya Investment Management LLC1.01MUS$32.5MSep 30, 2026
Sun Life1.01MUS$32.2MSep 30, 2026
Citadel990KUS$31.7MSep 30, 2026
Fred Alger Management, LLC933KUS$29.9MSep 30, 2026
Squadron Capital Management LLC915KUS$29.3MSep 30, 2026
Nuveen876KUS$28MSep 30, 2026
Elmind Capital, LP867KUS$27.8MSep 30, 2026
Balyasny Asset Management L.P.813KUS$26MSep 30, 2026
Point72 Asset Management, L.P.790KUS$25.3MSep 30, 2026
Ameriprise764KUS$24.5MSep 30, 2026

This page holds 50 of 308 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund5.16MUS$200MJun 30, 2026
iShares Russell 2000 ETF4.28MUS$166MJun 30, 2026
Vanguard Small-Cap Index Fund3.72MUS$144MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF3.17MUS$123MJun 30, 2026
Fidelity Small Cap Growth Fund2.51MUS$97.7MJul 31, 2026
Vanguard Small-Cap Value Index Fund2.36MUS$91.3MJun 30, 2026
Vanguard Extended Market Index Fund1.96MUS$75.8MJun 30, 2026
Fidelity OTC Portfolio1.87MUS$72.9MJul 31, 2026
Fidelity Advisor Biotechnology Fund1.83MUS$71.4MJul 31, 2026
Fidelity Small Cap Index Fund1.82MUS$70.9MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Select Health Care Portfolio1.75MUS$61.2MMay 31, 2026
Lord Abbett Growth Leaders Fund1.73MUS$67.3MJul 31, 2026
Select Biotechnology Portfolio1.6MUS$56.1MMay 31, 2026
iShares Russell 2000 Growth ETF1.54MUS$59.6MJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio1.41MUS$49.2MMay 29, 2026
Fidelity Stock Selector Small Cap Fund1.36MUS$52.8MJul 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund1.34MUS$46.9MMay 31, 2026
Fidelity Small Cap Growth K6 Fund1.25MUS$48.6MJul 31, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1.13MUS$43.6MJun 30, 2026
Small Cap Growth Fund1.09MUS$42.5MJul 31, 2026
T. Rowe Price New Horizons Fund, Inc.1.09MUS$42.1MJun 30, 2026
Lord Abbett Developing Growth Fund Inc1.06MUS$41.2MJul 31, 2026
iShares Biotechnology ETF1.04MUS$40.3MJun 30, 2026
Fidelity Advisor Health Care Fund920KUS$35.8MJul 31, 2026
Fidelity Series Small Cap Opportunities Fund801KUS$31.2MJul 31, 2026
Fidelity Extended Market Index Fund788KUS$27.5MMay 31, 2026
Invesco Discovery Fund741KUS$25.9MMay 31, 2026
Fidelity Puritan Fund740KUS$25.9MMay 31, 2026
Schwab U.S. Small-Cap ETF739KUS$25.8MMay 31, 2026
Vanguard Russell 2000 Index Fund735KUS$25.7MMay 31, 2026
Fidelity Balanced Fund718KUS$25.1MMay 31, 2026
SmallCap Growth Fund I611KUS$23.8MJul 31, 2026
Vanguard Explorer Fund608KUS$23.7MJul 31, 2026
Fidelity U.S. Equity Central Fund600KUS$23.2MJun 30, 2026
Janus Henderson Triton Fund583KUS$22.6MJun 30, 2026
JNL/Invesco Small Cap Growth Fund561KUS$21.7MJun 30, 2026
Janus Henderson Global Life Sciences Fund519KUS$20.1MJun 30, 2026
Invesco Small Cap Growth Fund515KUS$19.9MJun 30, 2026
Fidelity Advisor Equity Growth Fund512KUS$17.9MMay 31, 2026
Fidelity Fund477KUS$18.5MJun 30, 2026
Fidelity Advisor New Insights Fund464KUS$17.9MJun 30, 2026
Fidelity Small Cap Discovery Fund445KUS$17.3MJul 31, 2026
Fidelity Advisor Small Cap Fund417KUS$14.6MMay 31, 2026
VIP Growth Portfolio409KUS$15.8MJun 30, 2026
Franklin Small Cap Growth Fund407KUS$15.8MJul 31, 2026
Schwab Small-Cap Index Fund405KUS$15.8MJul 31, 2026
Emerald Growth Fund382KUS$14.9MJul 31, 2026
Emerald Growth Fund382KUS$13.7MApr 30, 2026
Fidelity Series Small Cap Discovery Fund381KUS$14.8MJul 31, 2026
MFS New Discovery Fund367KUS$12.8MMay 31, 2026

This page holds 50 of 351 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Morris Arlene
Director
Sale42,349USD 37.09US$1.57MAug 27, 2026
Morris Arlene
Director
Sale3,161USD 37.54US$119KAug 27, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC15.00%16.6MDec 31, 2024Schedule 13G
Fairmount Funds Management LLC8.60%15.4MMar 31, 2026Schedule 13D
BlackRock, Inc.8.00%13.6MJun 30, 2026Schedule 13G
Vanguard Capital Management LLC5.08%8.69MJun 30, 2026Schedule 13G
Kynam Capital Management, LP4.33%6.17MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert J Perez
Other companies: Rapport Therapeutics, Inc. (Director · Since at least Nov 7, 2024); Immunocore Holdings plc (Director · Jan 2, 2024 – Jan 2, 2024 · Past); Third Harmonic Bio Inc. (Director · Sep 14, 2022 – Mar 6, 2023 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 22, 2023 · Past); Spark Therapeutics Inc (Director · Jan 3, 2018 – Dec 17, 2019 · Past); Larimar Therapeutics, Inc. (Director · Sep 24, 2015 – Jun 26, 2019 · Past); Decoy Therapeutics Inc. (Director · Sep 2, 2015 – Jul 26, 2017 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Jun 22, 2017 · Past); AMAG Pharmaceuticals Inc (Director · Jan 26, 2009 – May 16, 2019 · Past); Cubist Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 3, 2006 – Jan 21, 2015 · Past)
Director · Mar 28, 2018 – Jun 14, 2019 · Past
Arlene Morris
Other companies: Edgewise Therapeutics, Inc. (Director · Since at least May 6, 2024); Palatin Technologies, Inc. (Director · Since at least Jun 22, 2022); Viridian Therapeutics, Inc. (Chief Executive Officer, Willow Advisors · Since at least Jun 8, 2022); Viveve Medical, Inc. (Director · Jan 3, 2023 – Jan 3, 2023 · Past)
Director · Since at least Jun 7, 2022
Chris Cain
Other companies: Damora Therapeutics, Inc. (Board Director · Since at least Nov 10, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Viridian Therapeutics, Inc. (Director · Since at least Mar 10, 2025)
Director · Since at least Jul 6, 2020
Matthew Ros
Other companies: Verastem, Inc. (Chief Operating Officer · Jan 14, 2025 – Nov 4, 2026 · Past); Epizyme Inc (See Remarks · May 16, 2016 – Aug 16, 2021 · Past)
Pharma-Biotech Executive · Since at least Jul 26, 2019
Peter Harwin
Other companies: Oruka Therapeutics, Inc. (Director · Since at least Nov 5, 2026); Damora Therapeutics, Inc. (Chairman of the Board · Since at least May 12, 2026)
Founding Partner, Fairmount Funds Management LLC · Since at least Nov 4, 2026
Chris Cain
Other companies: Jade Biosciences, Inc. (Director of Research, Fairmount · Since at least Nov 4, 2026)
Member of the Compensation Committee, Chair of the Science & Technology Committee · Since at least Nov 4, 2026
John Green
Other companies: Merrimack Pharmaceuticals Inc (Principal Accounting Officer · Jun 14, 2017 – Jun 14, 2017 · Past)
Chief Financial Officer · Since at least Jan 31, 2019
Jorn Aldag
Other companies: Hookipa Pharma Inc (Chief Executive Officer, Director · Apr 17, 2019 – Apr 15, 2024 · Past)
Director · Mar 28, 2018 – Jul 1, 2020 · Past
Karen Ferrante
Other companies: MacroGenics, Inc. (Director · Since at least May 13, 2021)
Director · Since at least Oct 1, 2020
Todd Shegog
Other companies: Forma Therapeutics Holdings Inc (SVP, Chief Financial Officer · Jun 18, 2020 – Oct 14, 2022 · Past)
Pharma-Biotech Executive · Since at least Feb 22, 2021
All 20 people
PersonSeat
Andrew RobbinsChief Executive Officer & President · Since at least Dec 17, 2025
Brad BarnettChief Technology Officer · Since at least Nov 5, 2026
Charles WilsonChief Executive Officer, Director · Mar 28, 2018 – Mar 1, 2019 · Past
Christi WaarichSenior Director, Investor Relations · Since at least Sep 15, 2026
Cole PinnowChief Commercial Officer · Since at least Dec 17, 2025
Erin SchellhammerChief People Officer · Since at least Nov 5, 2026
Evan KearnsChief Legal Officer · Since at least Jan 23, 2024
Geoffrey HodgeChief Technical Officer · Mar 1, 2019 – Feb 11, 2020 · Past
Jessica SachsChief Medical Officer · Since at least Nov 5, 2026
John RobinsonChief Scientific Officer · Since at least Mar 31, 2021

Open People

Log in to ask 6ix AI your own questions about Cogent Biosciences, Inc.